Protagenic Therapeutics Warrant
PTIXW
PTIXW was delisted on the 2nd of January, 2026.
2 hedge funds and large institutions have $7.79K invested in Protagenic Therapeutics Warrant in 2022 Q4 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.6% less ownership
Funds ownership: 1.77% → 1.16% (-0.6%)
33% less funds holding
Funds holding: 3 → 2 (-1)
40% less capital invested
Capital invested by funds: $13K → $7.79K (-$5.21K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$151 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$3.98K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WAM
1
Warberg Asset Management
Winnetka,
Illinois
| $7.26K | -$3.98K | -108,301 | -38% |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $527 | +$151 | +4,124 | +21% |
|
PTIXW Hedge Fund Activity: Q4 2022 in Review
2 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Protagenic Therapeutics Warrant (PTIXW) for Q4 2022, worth a combined $7.79K — down 40% from $13K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of PTIXW and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.
The largest buyer was Susquehanna International Group, adding an estimated $151. The largest seller was Warberg Asset Management, cutting an estimated $3.98K.
- 2 institutional investors held Protagenic Therapeutics Warrant (PTIXW) as of Q4 2022, down from 3 in Q3 2022.
- Funds reported $7.79K of Protagenic Therapeutics Warrant stock for Q4 2022, down 40% quarter-over-quarter.
- 0 funds opened new Protagenic Therapeutics Warrant positions in Q4 2022 and 1 closed out, a net change of -1 holder.
- The largest Protagenic Therapeutics Warrant buyer in Q4 2022 was Susquehanna International Group, an estimated $151 added.
- The largest Protagenic Therapeutics Warrant seller in Q4 2022 was Warberg Asset Management, an estimated $3.98K sold.
Based on aggregated 13F filings for Q4 2022.